Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women
- PMID: 39716293
- PMCID: PMC11667832
- DOI: 10.1186/s13018-024-05361-z
Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women
Abstract
Background: The influence of the glucagon-like peptide-1 receptor (GLP-1R) on bone metabolism is well-established. However, it has been observed that single nucleotide polymorphisms (SNPs) in the GLP-1R gene can partially affect its function. Therefore, this study aims to investigate the association between SNPs in the GLP-1R gene and postmenopausal osteoporosis (PMOP) within the Chinese Han population.
Methods: This study employed a cross-sectional case-control design, recruiting a total of 152 participants, including 76 patients with osteoporosis (OP) (case group) and 76 healthy individuals (control group). Seven tag SNPs of GLP-1R were selected from the National Center of Biotechnology Information and Genome Variation Server. The association between GLP-1R polymorphisms and PMOP risk was assessed using different genetic models and haplotypes, while also exploring SNP-SNP and SNP-environment interactions.
Results: Our results showed that minor alleles A at rs3765468, A at rs3765467 and G at rs4714210 showed significant associations with an increased risk of OP. Individuals with rs3765468 AG-AA genotype and rs3765467 AG-AA genotype exhibited a significantly higher risk of PMOP. Moreover, haplotype analysis revealed a significant association of the GACACA haplotype on PMOP risk (P = 0.033). Additionally, a multiplicative interaction was observed between rs3765468 and rs3765467 that was associated with an increased risk of PMOP (Pinteraction = 0.012).
Conclusions: Specific SNPs in the GLP-1R gene were linked to an increased risk of PMOP. This study improves our understanding of the genetic basis of PMOP in this population and suggests that genetic screening can identify individuals at risk for developing PMOP, enabling early prevention.
Keywords: Bone mineral density; Glucagon-like peptide-1 receptor; Haplotype; Postmenopausal osteoporosis; Single-nucleotide polymorphism.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Consent for publication: I certify that this manuscript is a unique submission and is not being considered for publication, in part or in full, with any other source in any medium. Ethics approval and consent to participate: The study protocol was approved by the Medical Ethics Committee of the Hebei Medical University Third Hospital [NO.2023–026-1]. The participants were required to provide written informed consent in accordance with the principles outlined in the Declaration of Helsinki prior to their participation in the study.
Figures
Similar articles
-
Polymorphisms in the glucagon-like peptide-1 receptor gene and their interactions on the risk of osteoporosis in postmenopausal Chinese women.PLoS One. 2023 Dec 14;18(12):e0295451. doi: 10.1371/journal.pone.0295451. eCollection 2023. PLoS One. 2023. PMID: 38096145 Free PMC article.
-
Relationship between glucagon-like peptide-1 receptor gene polymorphism and bone mineral density in postmenopausal women in Shanghai.Ann Palliat Med. 2020 Jul;9(4):1732-1741. doi: 10.21037/apm-19-396. Epub 2020 Jun 8. Ann Palliat Med. 2020. PMID: 32527131
-
Common variants in MAEA gene contributed the susceptibility to osteoporosis in Han Chinese postmenopausal women.J Orthop Surg Res. 2021 Jan 10;16(1):38. doi: 10.1186/s13018-020-02140-4. J Orthop Surg Res. 2021. PMID: 33423677 Free PMC article.
-
The transforming growth factor-β1 (TGF-β1) gene polymorphisms (TGF-β1 T869C and TGF-β1 T29C) and susceptibility to postmenopausal osteoporosis: a meta-analysis.Medicine (Baltimore). 2015 Jan;94(4):e461. doi: 10.1097/MD.0000000000000461. Medicine (Baltimore). 2015. PMID: 25634187 Free PMC article. Review.
-
Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.Am J Med Sci. 2025 Jan;369(1):126-130. doi: 10.1016/j.amjms.2024.06.030. Epub 2024 Jul 8. Am J Med Sci. 2025. PMID: 38986908 Review.
Cited by
-
Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis.J Orthop Surg Res. 2025 Feb 7;20(1):147. doi: 10.1186/s13018-025-05545-1. J Orthop Surg Res. 2025. PMID: 39920732 Free PMC article.
-
Therapeutic potential of total flavonoids of Rhizoma Drynariae: inhibiting adipogenesis and promoting osteogenesis via MAPK/HIF-1α pathway in primary osteoporosis.J Orthop Surg Res. 2025 Mar 11;20(1):260. doi: 10.1186/s13018-025-05665-8. J Orthop Surg Res. 2025. PMID: 40069718 Free PMC article.
-
Transcriptome sequencing-based analysis of the molecular mechanism underlying the effect of lncRNA AC003090.1 on osteoporosis.J Orthop Surg Res. 2025 Apr 7;20(1):346. doi: 10.1186/s13018-025-05634-1. J Orthop Surg Res. 2025. PMID: 40189548 Free PMC article.
-
A-485 alleviates postmenopausal osteoporosis by activating GLUD1 deacetylation through the SENP1-Sirt3 signal pathway.J Orthop Surg Res. 2025 May 29;20(1):542. doi: 10.1186/s13018-025-05839-4. J Orthop Surg Res. 2025. PMID: 40442713 Free PMC article.
-
Effects of traditional Chinese medicine Zuo-Gui-Wan on gut microbiota in an osteoporotic mouse model.J Orthop Surg Res. 2025 Feb 1;20(1):128. doi: 10.1186/s13018-025-05504-w. J Orthop Surg Res. 2025. PMID: 39891262 Free PMC article.
References
-
- Compston JE, McClung MR, Leslie WD. Osteoporosis Lancet. 2019;393(10169):364–76. 10.1016/S0140-6736(18)32112-3. - PubMed
-
- Yu F, Xia W. The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos. 2019;14(1):32. 10.1007/s11657-018-0549-y. - PubMed
-
- Migliorini F, Colarossi G, Baroncini A, Eschweiler J, Tingart M, Maffulli N. Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion. Expert Rev Clin Pharmacol. 2021;14(1):105–19. 10.1080/17512433.2021.1851192. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
